Daunorubicin-Induced Cardiovascular Effects in Ts65Dn Mouse Model of Down Syndrome

This study investigated chronic cardiovascular toxicity from daunorubicin chemotherapy in adult mice with Down syndrome (Ts65Dn model) versus normal mice, finding that Down syndrome mice show increased susceptibility to treatment-related cardiac dysfunction including altered ejection fraction and increased arterial stiffness. The findings support clinical observations that adults with Down syndrome have elevated risk for heart failure following anthracycline chemotherapy.